522-48-5 Usage
Description
2-Tetralin-1-yl-4,5-dihydro-1H-imidazole hydrochloride, also known by its brand names Tetryzoline Hydrochloride (JAN) and Tetrahydrozoline Nitrate (JAN), is an off-white solid with chemical properties that make it a potent alpha agonist. It is primarily recognized for its ability to constrict conjunctival blood vessels, which is a significant application in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
2-Tetralin-1-yl-4,5-dihydro-1H-imidazole hydrochloride is used as an alpha agonist for its vasoconstrictive properties. It is particularly effective in causing constriction of conjunctival blood vessels, which helps to relieve the redness left by ocular irritants.
Used in Over-the-Counter Eye Drops:
2-Tetralin-1-yl-4,5-dihydro-1H-imidazole hydrochloride is widely utilized in the formulation of over-the-counter eye drops, where it serves as an active ingredient to address the issue of redness in the eyes. The constriction of blood vessels reduces the appearance of redness, providing a cosmetic benefit to users seeking relief from the discomfort and unsightly appearance caused by ocular irritants.
Originator
Tyzine,Pfizer,US,1954
Manufacturing Process
A mixture of 540 grams (9.0 mols) of ethylenediamine, 270 grams (1.53
mols) of 1,2,3,4tetrahydro-α-naphthoic acid, and 360 ml (4.32 mols) of
concentrated hydrochloric acid was introduced into a two-liter, three-necked
flask fitted with a thermometer, stirrer, and distillation takeoff. The mixture
was distilled under a pressure of about 20 mm of mercury absolute until the
temperature rose to 210°C. Thereafter, heating was continued under
atmospheric pressure and when the temperature reached about 260°C, an
exothermic reaction was initiated. The heat was then adjusted to maintain a
reaction temperature of 275° to 280°C for 45 minutes and the mixture
thereafter cooled to room temperature.900 ml of 4 N hydrochloric acid was added and the aqueous layer stirred with
warming until a clear, brown solution resulted. This brown solution was made
strongly alkaline with sodium hydroxide. The oil that separated solidified and
was collected on a filter leaving filtrate A. The solid was dissolved in 370 ml of
alcohol with warming, and the solution was treated with 130 ml of
concentrated hydrochloric acid with stirring and cooling. This acidified mixture
was diluted with 300 ml of ether and chilled. The solid salt was collected and
dried and the filtrate concentrated to approximately 300 ml, diluted with 300
ml of ether and the salt which separated collected and dried.Filtrate A was extracted with ether, dried, acidified with alcoholic hydrogen
chloride, and the salt which separated was collected and dried. There was
thus obtained, when all the salt had been combined, 250 grams (69.3% of the
theoretical yield) of 2-(1,2,3,4-tetrahydro-1-naphthyl)imidazoline
hydrochloride, melting at 256° to 257°C.
Therapeutic Function
Nasal decongestant, Pharmaceutic aid
Check Digit Verification of cas no
The CAS Registry Mumber 522-48-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,2 and 2 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 522-48:
(5*5)+(4*2)+(3*2)+(2*4)+(1*8)=55
55 % 10 = 5
So 522-48-5 is a valid CAS Registry Number.
InChI:InChI=1/C13H16N2.ClH/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13;/h1-2,4,6,12H,3,5,7-9H2,(H,14,15);1H
522-48-5Relevant articles and documents
Non-aqueous oil delivery system for ophthalmic drugs
-
, (2010/12/31)
The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil vehicle delivery system are as therapeutically effective in man and animals as the corresponding higher concentrations of ophthalmic drugs that are commercially used in aqueous solutions. Eye drops that utilize this nonaqueous oil delivery system, when used in man, are comfortable to use and produce little ocular irritation, have a longer shelf-life, low systemic toxic potential, and only short term blurring of vision. Using this nonaqueous oil delivery system, a single drop of ophthalmic drug with a concentration that is 10 times less than the same drug used in commercially available aqueous eye drops is as effective as the commercially available aqueous ophthalmic eye drops that require many applications to be effective. In addition, utilizing the nonaqueous oil delivery system as eye drops produces no ocular sensation of burning, stinging or excessive tearing that is commonly associated with the commercially available aqueous eye drops. This very dilute ophthalmic drug preparation has a greatly reduced systemic toxicity potential as compared to the commercially used aqueous ophthalmic drops. The vehicle includes castor oil, corn oil, glycerol, mineral oil USP, vegetable oil, white petrolatum USP, and mixtures, there of. The ophthalmic class of drugs includes antimicrobials, miotics, mydriatics, mydriatic-cycloplegics, mydriatic-cycloplegic reversal agents and topical anesthetics.
Pharmaceutical composition for ophthalmic use comprising a nonsteroidal anti-inflammatory and a decongestant drug
-
, (2008/06/13)
A pharmaceutical aqueous solution for ophthalmic use comprising a nonsteroidal anti-inflammatory drug, having a carboxylic group, a decongestant drug and a mixture of a polysorbate and a poloxamer.
